Changes in biological markers, particularly hormone receptors, due to pre-operative chemotherapy (epirubicin/docetaxel) in operable breast cancer

Oncology Reviews

Volumn 2, Issue 4, 2008, Pages 229-234

  Tashima, Rumiko ^a   Nishimura, Reiki ^b  

^a KUMAMOTO CHUO HOSPITAL   (Japan)

^b KUMAMOTO CITY HOSPITAL   (Japan)

Author keywords

Amenorrhea; Estrogen receptor; Pre operative chemotherapy; Progesterone receptor

Indexed keywords

EID: 77958090790     PISSN: 19705557     EISSN: 19705565     Source Type: Journal    
DOI: 10.1007/s12156-008-0079-8     Document Type: Review

References (23)

1. Inaji H, Komoike Y, Motomura K et al (2002) The role of neoadjuvant chemotherapy for breast cancer treatment. Jpn J Cancer Chemother 29:1113-1119
2. Bernard F, John B, Norman W et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685
3. Nishimura R, Nagao K, Miyayama H et al (2002) An evaluation of predictive factors involved in clinical or pathological response to primary chemotherapy in advanced breast cancer. Breast Cancer l9:145-152
4. Hirano A, Shimizu T, Imamura H et al (2006) The combination of Epirubicin plus Docetaxel as neoadjuvant chemotherapy in locally advanced breast cancer. Anticancer Res 26:581-584 (Pubitemid 43206020)
5. Steger GG, Galid A, Gunat M (2007) ABCSG-14: Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granlocyte colony -stimulating factor in operable breast cancer: results of ABCSG-14: J Clin Oncol 25:2012-2018 (Pubitemid 46972785)
6. van der Hage JA, van de Velde CJH, Jean-Pierre J et al (2001) Preoperative chemotherapy in primary operable breast cancer: results from the european organization for research and treatment of cancer trial 10902. J Clin Oncol 19: 4224-4237
7. Chua S, Smith IE, Hern RPA et al (2005) Neoadjuvant vinorelbine/ epirubicin (VE) versus standard adiamycin/cyclophosphmide (AC) in operable breast cancer; analysis of response and tolerability in a randomized phase III trial (TOPIC2). Ann Oncol 16:1435-1441 (Pubitemid 41222415)
8. Gunter VM, Günter R, Angelika C et al (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23:2676-2685
9. Kobayashi T, Yamasaki H, Nakamura T et al (2001) Breast cancer. Jpn Cancer Chemother 28:1814-1825
10. Matsuo K, Fukutomi T, Watanabe T (2001) Clinicopathological effect of neoadjuvant chemotherapy with doxorubicin and docetaxel in locally advanced breast carcinoma. Jpn J Breast Cancer 16:200-203
11. Burcombe RJ, Makris A, Richman PI et al (2005) Evaluation of ER,PgR,HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 92:147-155 (Pubitemid 40188448)
12. Fukutomi T (2002) Option of the surgical mode for breast cancer based on the effect of neoadjuvant chemotherapy. J Jpn Surg Soc 103:803-805
13. Monir HED, Mohanmed MM, Hussein MK et al (2000) Pathological assessment of the response of locally advanced breast cancer to neoadjuvant chemotherapy and its implication for surgical management. Surg Today 30:249-254
14. Inaji H, Komoike Y, Motomura K et al (2002) Breast-conserving treatment after neoadjuvant chemotherapy in large breast cancer. Breast Cancer 9:20-25
15. Sarakbi WAI, Salhab M, Thomas V et al (2005) Is preoperative core biopsy accurate in determining the hormone receptor status in women with invasive breast cancer? Int Semin Surgical Oncol 2:15
16. Chang J, Powles TJ, Allred DC et al (1999) Biologic marker as predictor of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17:3058-3063 (Pubitemid 29470633)
17. Bottini A, Berruti A, Bersiga A (1996) Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer Res 16:3105-3110 (Pubitemid 26390257)
18. Makris A, Powles TJ, Allred DC et al (1999) Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study. Breast Cancer Res Treat 53:51-59 (Pubitemid 29123619)
19. Lo SS, Wang HC, Shyr YM, Lui WY (1994) Can the hormonal receptor status of primary breast cancer be altered by neoadjuvant chemotherapy. J Surg Oncol 57:94-96
20. Jain V, Landry M, Levine EA (1996) The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma. Am Surg 62:162-165 (Pubitemid 26162285)
21. Taucher S, Rudas M, Gnant M (2003) Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocrine-Related Cancer 10:91-98 (Pubitemid 36457240)
22. Jonat W, Kaufmann M, Sauerbrei W et al (2002) Early breast cancer research association study: goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20:4628-4635 (Pubitemid 36025278)
23. Bines J, Oleske DM, Cobleigh M (1996) Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718-1729 (Pubitemid 26134232)